Investigational drug · Phase 2
ASP2767
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glaucoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ASP2767"
First trial start
2026
Oct 7, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASP2767", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glaucoma
Approved drugs for the same conditions: Glaucoma · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ASP2767" as an intervention, largest first.
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Glaucoma
- Bimatoprost Implant SystemPhase 33 trials
SpyGlass Pharma, Inc. · Cataract, Glaucoma, Ocular Hypertension
- Timolol eye drops 0.5%Phase 33 trials
Glaukos Corporation · Glaucoma, Ocular Hypertension
- Gen 2 Travoprost Intracameral ImplantGen 2 Travoprost Intraocular ImplantPhase 32 trials
Glaukos Corporation · Glaucoma
- Inactive controlQLS-111 vehiclePhase 32 trials
Can-Fite BioPharma · Hepatocellular Carcinoma, Cirrhosis, Open-angle Glaucoma (OAG)
- QLS-111Phase 23 trials
Qlaris Bio, Inc. · Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG)
- BL1107Phase 22 trials
Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma
- intraocular implant releasing timololTimoD implantPhase 21 trial
EyeD Pharma · Glaucoma, Ocular Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.